Zomedica Launches Two New Quantitative Assays on the TRUFORMA(R) Platform: Canine NT-proBNP and Progesterone
Zomedica (NYSE American:ZOM) has launched two new canine assays for its TRUFORMA In-Clinic Biosensor Testing Platform. The first is a canine NT-proBNP test for detecting cardiac conditions, which helps distinguish cardiac from respiratory disease and identifies dogs at risk of congestive heart failure. The second is a progesterone test for determining optimal breeding dates and detecting reproductive disorders.
These additions bring the total to 8 new assays launched in the past 18 months. Both tests deliver quantitative results in under 20 minutes with reference lab accuracy. The NT-proBNP test is particularly significant as 1 in 10 dogs experience heart disease, while the progesterone assay addresses a high demand market with 4 million puppies born annually in the US. Zomedica offers these diagnostics without requiring capital outlay or monthly minimums from veterinary practices.
Zomedica (NYSE American:ZOM) ha lanciato due nuovi test per cani per la sua piattaforma di test biosensoriali TRUFORMA in clinica. Il primo è un test NT-proBNP per cani per la rilevazione di condizioni cardiache, che aiuta a distinguere le malattie cardiache da quelle respiratorie e identifica i cani a rischio di insufficienza cardiaca congestizia. Il secondo è un test del progesterone per determinare le date ottimali per l'allevamento e rilevare disturbi riproduttivi.
Questi aggiustamenti portano il totale a 8 nuovi test lanciati negli ultimi 18 mesi. Entrambi i test forniscono risultati quantitativi in meno di 20 minuti con l'accuratezza di un laboratorio di riferimento. Il test NT-proBNP è particolarmente significativo poiché 1 cane su 10 soffre di malattie cardiache, mentre il test del progesterone risponde a un mercato ad alta domanda con 4 milioni di cuccioli nati annualmente negli Stati Uniti. Zomedica offre queste diagnostiche senza richiedere un investimento iniziale o minimi mensili da parte delle cliniche veterinarie.
Zomedica (NYSE American:ZOM) ha lanzado dos nuevas pruebas caninas para su Plataforma de Pruebas Biosensor TRUFORMA en Clínica. La primera es un test de NT-proBNP canino para detectar condiciones cardíacas, que ayuda a distinguir enfermedades cardíacas de enfermedades respiratorias e identifica a los perros en riesgo de insuficiencia cardíaca congestiva. La segunda es un test de progesterona para determinar las fechas óptimas de cría y detectar trastornos reproductivos.
Estas adiciones elevan el total a 8 nuevas pruebas lanzadas en los últimos 18 meses. Ambas pruebas proporcionan resultados cuantitativos en menos de 20 minutos con precisión de laboratorio de referencia. La prueba de NT-proBNP es particularmente significativa ya que 1 de cada 10 perros sufre de enfermedades cardíacas, mientras que la prueba de progesterona responde a un mercado de alta demanda con 4 millones de cachorros nacidos anualmente en los EE. UU. Zomedica ofrece estos diagnósticos sin requerir inversión inicial o mínimos mensuales por parte de las prácticas veterinarias.
조메디카 (NYSE American:ZOM)는 TRUFORMA 클리닉 바이오센서 테스트 플랫폼을 위해 두 가지 새로운 개 테스트를 출시했습니다. 첫 번째는 심장 질환을 감지하는 개 NT-proBNP 테스트로, 심장 질환과 호흡기 질환을 구분하는 데 도움을 주고 심부전이 위험한 개를 식별합니다. 두 번째는 최적의 번식 날짜를 결정하고 생식 장애를 감지하기 위한 프로게스테론 테스트입니다.
이러한 추가 사항은 지난 18개월 동안 출시된 새 테스트를 총 8개로 늘립니다. 두 테스트 모두 20분 이내에 정량적 결과를 제공하며, 기준 실험실의 정확도를 갖추고 있습니다. NT-proBNP 테스트는 10마리 중 1마리가 심장 질환을 앓고 있다는 점에서 특히 중요하며, 프로게스테론 테스트는 미국에서 매년 400만 마리의 강아지가 태어나는 높은 수요 시장에 대응합니다. 조메디카는 이러한 진단을 위해 동물 병원으로부터 초기 자본이나 월 최소 금액을 요구하지 않습니다.
Zomedica (NYSE American:ZOM) a lancé deux nouveaux tests canins pour sa plateforme de test biosensoriel TRUFORMA en clinique. Le premier est un test NT-proBNP canin visant à détecter les problèmes cardiaques, qui aide à distinguer les maladies cardiaques des maladies respiratoires et identifie les chiens à risque d'insuffisance cardiaque congestive. Le second est un test de progestérone pour déterminer les dates optimales de reproduction et détecter les troubles reproductifs.
Ces ajouts portent le total à 8 nouveaux tests lancés au cours des 18 derniers mois. Les deux tests fournissent des résultats quantitatifs en moins de 20 minutes avec une précision de laboratoire de référence. Le test NT-proBNP est particulièrement significatif car 1 chien sur 10 souffre de maladies cardiaques, tandis que le test de progestérone répond à un marché à forte demande avec 4 millions de chiots nés chaque année aux États-Unis. Zomedica offre ces diagnostics sans exiger de dépenses d'investissement ou de montants minimaux mensuels de la part des cliniques vétérinaires.
Zomedica (NYSE American:ZOM) hat zwei neue Hundetests für seine TRUFORMA In-Clinic Biosensor-Testplattform eingeführt. Der erste ist ein NT-proBNP-Test für Hunde, der herzbedingte Erkrankungen erkennt, dabei hilft, Herz- von Atemwegserkrankungen zu unterscheiden und Hunde mit einem Risiko für Herzinsuffizienz zu identifizieren. Der zweite Test ist ein Progesterontest, der optimale Zuchttermine bestimmt und reproduktive Störungen erkennt.
Durch diese Erweiterungen erhöht sich die Gesamtzahl der in den letzten 18 Monaten eingeführten neuen Tests auf 8. Beide Tests liefern quantitative Ergebnisse in weniger als 20 Minuten mit der Genauigkeit eines Referenzlabors. Der NT-proBNP-Test ist besonders bedeutend, da 1 von 10 Hunden an Herzkrankheiten leidet, während der Progesterontest einen stark nachgefragten Markt bedient, in dem jährlich 4 Millionen Welpen in den USA geboren werden. Zomedica bietet diese Diagnosetests an, ohne dass eine Investition oder monatliche Mindestbeträge von den Tierarztpraxen erforderlich sind.
- Added 8 new assays to TRUFORMA platform in past 18 months
- Tests provide results in under 20 minutes with reference lab accuracy
- No capital outlay or monthly minimums required from veterinary practices
- Addresses large market opportunity (1 in 10 dogs affected by heart disease)
- Expands into cardiac and reproductive diagnostic segments
- None.
Insights
With the addition of these two new assay launches, Zomedica has added 8 new assays in the past 18 months to the rapidly growing TRUFORMA Platform
ANN ARBOR, MI / ACCESSWIRE / December 23, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the launch of two new canine assays for the TRUFORMA In-Clinic Biosensor Testing Platform.
Zomedica's canine NT-poBNP test is used for the quantitative detection of NT-proBNP in canine EDTA plasma or serum. Elevated NT-proBNP can be indicative of conditions such as congestive heart failure, assisting in the diagnosis and management of cardiac conditions in dogs. This test distinguishes cardiac from respiratory disease, identifies dogs at high risk of congestive heart failure, aids with chronic monitoring of dogs with myxomatous mitral valve degeneration all with reference lab accuracy.
"It is estimated that 1 in 10 dogs will experience heart disease in their life and unfortunately, most go undetected," said Dr. Kelli Puccio, a Professional Services Veterinarian for Zomedica. "Diagnosing and evaluating cardiac disease in our canine patients can be challenging. The TRUFORMA canine NT-proBNP assay facilitates the early detection of canine heart disease with the convenience of results in just a few minutes. This provides veterinarians with the ability to start treatments and schedule advanced diagnostic tests more quickly. Increasing our patients' quality of life earlier in the disease process." Additionally, this assay runs on either plasma or serum allowing more flexibility within a clinic's natural workflow.
Zomedica's progesterone testing is used for quantitative detection of the levels of progesterone in canine serum. This will aide in determining optimal breeding dates, predicting parturition dates or timing a cesarean section, and detecting reproductive disorders with the same accuracy as the reference lab but with in-clinic convenience.
Zomedica's new progesterone assay has been one of the most frequently requested assays from practitioners, which is unsurprising when there are 4 million puppies born in the US every year.
"When measuring progesterone, we need to take serial blood draws every couple of days, states Dr. Puccio. "The TRUFORMA canine progesterone assay provides accurate serial quantitative progesterone measurements in clinic. This will permit veterinarians to recognize the optimal breeding window more efficiently, allowing for more successful breeding cycles."
"We are very excited to add two additional canine assays for the TRUFORMA platform," stated Ashley Wood, PhD, Zomedica's Vice President of Research & Development. "Canine NT-proBNP and progesterone expand the range of indications to now include cardiac and reproductive conditions, offering even more comprehensive insights and support for clinical decision-making. We remain committed to continuously improving our diagnostic platform, and we are confident that these new assays will bring added value to both veterinarians and pet patients alike."
Each of these new offerings deliver quantitative results available in less than 20 minutes with the same high level of precision that our TRUFORMA customers have grown accustomed to. Importantly, Zomedica offers this advanced diagnostic capability with no capital outlay or monthly minimums from veterinary practices. For more information, visit www.zomedica.com.
About Zomedica
Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi® Loop line of therapeutic devices and the TRUFORMA® diagnostic platform, the TRUVIEW™ digital cytology system, and the VetGuardian® no-touch monitoring system, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds
Follow Zomedica
Email Alerts: http://investors.zomedica.com
Facebook: https://m.facebook.com/zomedica
X (formerly Twitter): https://twitter.com/zomedica
Instagram: https://www.instagram.com/zomedica_inc
Cautionary Note Regarding Forward-Looking Statements
Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements, our ability to realize upon our business plans and cost control efforts and the impact of COVID-19 on our business, results and financial condition.
Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to successfully integrate acquisitions; uncertainty as to our ability to supply products in response to customer demand; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products, including acceptance of the TRUFORMA platform, canine NT-proBNP or progesterone assay; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including meeting distribution obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.
Investor Relations Contact:
Zomedica Investor Relations
investors@zomedica.com
1-734-369-2555
SOURCE: Zomedica Corp.
View the original press release on accesswire.com
FAQ
What are the two new assays Zomedica (ZOM) launched for the TRUFORMA platform?
How long does it take to get results from ZOM's new TRUFORMA assays?
How many new assays has ZOM added to TRUFORMA in the past 18 months?
What is the market potential for ZOM's new NT-proBNP cardiac test for dogs?
What are the financial requirements for veterinary practices to use ZOM's TRUFORMA platform?